Analyst Profile
Followed by 88 other investors
Lorenzo Biasio
Credit SuisseWall Street Analyst
Ranked #1,105 out of 8,014 Analysts on TipRanks (#1,968 out of 21,455 overall experts)
Success Rate
106 out of 166 Profitable Transactions
Average Return
8.00%
Average return per transaction
Time Frame
Compare to
If you copied Lorenzo Biasio's ratings since 2015 and opened each position for the duration of 1 Year:
63.86% of your transactions would have been profitable with an average return of 8.0%
Stock Rating Distribution
59.57% Buy
35.74% Hold
4.69% Sell
Distribution of Lorenzo Biasio's ratings
Additional Information
Main Sector:General
Geo Coverage:
US Market
UK Market
US MarketUK MarketBest Rating
The most profitable rating made by Lorenzo Biasio
Lorenzo Biasio's Stock Coverage
Lonza Group
Buy
Reiterated
―
+25.65%
4
BioMarin Pharmaceutical
Buy
Reiterated
$120.00
(24.88% Upside)
-31.20%
1
Novo Nordisk
Hold
Reiterated
kr335.00
(-56.61% Downside)
―
0.00%
4
Novo Nordisk
Hold
Reiterated
―
―
0.00%
8
Zimmer Biomet Holdings
Hold
Reiterated
$115.00
(-0.47% Downside)
+28.50%
3
AbbVie
Buy
Reiterated
―
+6.02%
10
Stryker
Hold
Reiterated
$95.00
(-56.82% Downside)
―
0.00%
3
Gilead Sciences
Buy
Reiterated
$115.00
(83.44% Upside)
-3.42%
6
Coloplast A/S
Hold
Reiterated
kr540.00
(-35.88% Downside)
+7.97%
14
Fresenius SE & Co. KGaA
Hold
Reiterated
€65.00
(163.44% Upside)
+42.50%
9
List of latest recommendations made by Lorenzo Biasio. Click to expand and see Lorenzo Biasio's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More